RSV Immunisation Pathfinder 1.0 Evaluation
In 2024, an RSV Immunisation Pathfinder Programme was established to offer nirsevimab to all infants born between 1st September 2024 and 28th February 2025, as well as other clinically high-risk infants less than 12 months of age. The aim of the programme was to reduce RSV-related illness among young infants.
Following completion of the programme, a multi-disciplinary working group convened by the National Health Protection Office (NHPO) carried out an evaluation to assess the effectiveness and efficiency of the RSV Immunisation Pathfinder Programme in Ireland, to inform future RSV immunisation policy.
Respiratory Syncytial Virus (RSV) Immunisation Pathfinder Programme 2024-2025 Evaluation – Executive Summary
07, Jan 2026
1.51 MB
Respiratory Syncytial Virus (RSV) Immunisation Pathfinder Programme 2024-2025 Evaluation – Technical Report
07, Jan 2026
5.56 MB
Information, Data and Reports for
Ireland’s specialist service for the surveillance of communicable diseases.